logo

For the Inventor, By the Inventor

Wuppertal, Germany

Egbert Wehinger

This inventor holds 66 USPTO granted patents, primarily in Dihydropyridine Compounds (CPC class 5462). Top assignees: Bayer Aktiengesellschaft, Baker Aktiengesellshaft. Active years: 1976-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Egbert Wehinger. Retrieved from https://idiyas.com/inventor/egbert-wehinger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 66

% Patents Active = 100.0

Average Co-Inventor Count = 4.2

ph-index = 11

Forward Citations = 444(Granted Patents)

Forward Citations (Not Self Cited) = 418(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Neviges, DE (1976 - 1981)
  • Velbert, DE (1979 - 1991)
  • Wuppertal, DE (1981 - 1999)

Company Filing History:

goldMedal65 out of 12,268 
 
Bayer Aktiengesellschaft
 patents
silverMedal1 out of 1 
 
Baker Aktiengesellshaft
 patent

Years Active: 1976-1999

Loading Chart...
Areas of Expertise:
Dihydropyridine
Antihypertensive
Ischaemia
Medicaments
Pyrazole Derivatives
Coronary Diseases
Vasodilating Agents
Optically Active Compounds
Pharmaceutical Compositions
Nitro-Substituted
Sulphur-Containing
2-Alkyleneaminodihydropyridines
66 patents (USPTO):Explore Patents
1. 5955482 - Use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters as medicaments (1999-09-21),
2. 5665741 - 1,4-dihydropyridine-3,5-dicarboxylic acid esters in treatment of (1997-09-09),
3. 4988717 - Optically active 1,4-dihydropyridine esters useful for treating (1991-01-29),
4. 4849433 - The compound, (1989-07-18),
5. 4798840 - Coronary-active fluorine-containing 1,4-dihydropyridines (1989-01-17),
6. 4705794 - Ischaemia or hypoxia controlling compositions containing (1987-11-10),
7. 4703119 - Intermediates of optically active 1,4-dihydropyridines (1987-10-27),
8. 4680305 - Use of sulphonyldihydropyridines as medicaments for the treatment of (1987-07-14),
9. 4675329 - Isopropyl 2-(3-trifluoromethylphenoxy)-ethyl (1987-06-23),
10. 4622332 - Asymmetric diesters of Hantzsch dihydropyridines with hypotensive (1986-11-11),
11. 4621082 - Pyridopyrimidines, pharmaceutical compositions and use (1986-11-04),
12. 4568681 - Antihypertensive tetrahydropyridine 3,5 dicarboxylic acid esters (1986-02-04),
13. 4565824 - Certain nitratoalkyl ester dihydropyridines having antihypertensive (1986-01-21),
14. 4559350 - Antihypertensive tetrahydropyridine 3-cyano 5-carboxylic acid esters (1985-12-17),
15. 4551467 - Vasodilating cyanoalkyl esters of 1,4-dihydropyridines (1985-11-05),

Title: Egbert Wehinger: Pioneering Inventor in Medicinal Innovations

Introduction:

Egbert Wehinger, a distinguished inventor based in Wuppertal, DE, has made significant contributions to the field of medicinal innovations. With an impressive portfolio of 65 patents, Wehinger has been at the forefront of developing novel medicaments for the treatment of various conditions.

Latest Patents:

His latest patents showcase his expertise in the use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters as medicaments, particularly for the treatment of the central nervous system. These innovative compounds have opened new possibilities in the realm of pharmaceuticals, offering hope for improved treatments and therapies.

Career Highlights:

Wehinger has a rich professional background, having worked with renowned companies such as Bayer Aktiengesellschaft and Baker Aktiengesellschaft. His extensive experience in the industry has been instrumental in shaping his inventive endeavors and pushing the boundaries of medical science.

Collaborations:

Throughout his career, Wehinger has collaborated with esteemed colleagues such as Harald Horstmann and Eike Moller. These collaborations have not only enriched his research and development process but have also fostered a spirit of innovation and teamwork in his projects.

Conclusion:

In conclusion, Egbert Wehinger stands as a trailblazer in the field of medicinal innovations, with a remarkable track record of patents and breakthroughs. His unwavering dedication to advancing healthcare through inventive solutions continues to inspire and drive progress in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…